Carlsmed (NASDAQ:CARL) Price Target Raised to $22.00

Carlsmed (NASDAQ:CARL) had its price target hoisted by research analysts at Needham & Company LLC from $17.00 to $22.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC‘s price objective points to a potential upside of 49.56% from the stock’s previous close.

Several other research analysts have also issued reports on the stock. Truist Financial lifted their price target on shares of Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Carlsmed in a research note on Wednesday, November 4th. Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, BTIG Research boosted their target price on Carlsmed from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.25.

Carlsmed Trading Down 8.3%

NASDAQ:CARL opened at $14.71 on Wednesday. The company has a 50-day moving average of $14.87 and a 200-day moving average of $12.52. The company has a debt-to-equity ratio of 0.18, a quick ratio of 8.66 and a current ratio of 8.84. Carlsmed has a twelve month low of $8.50 and a twelve month high of $17.23.

Carlsmed (NASDAQ:CARL) last released its earnings results on Tuesday, November 10th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. The business had revenue of $21.55 million for the quarter. Equities analysts expect that Carlsmed will post -1.50 earnings per share for the current year.

Institutional Investors Weigh In On Carlsmed

A number of large investors have recently made changes to their positions in CARL. Boston Partners lifted its position in shares of Carlsmed by 96.3% in the 3rd quarter. Boston Partners now owns 43,923 shares of the company’s stock valued at $618,000 after acquiring an additional 21,548 shares in the last quarter. Russell Investments Group Ltd. grew its position in Carlsmed by 85.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 257,805 shares of the company’s stock worth $3,627,000 after purchasing an additional 118,663 shares in the last quarter. Zevenbergen Capital Investments LLC raised its stake in Carlsmed by 50.4% during the 3rd quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company’s stock valued at $252,000 after purchasing an additional 6,000 shares during the period. Bank of America Corp DE acquired a new stake in Carlsmed during the 2nd quarter valued at $108,000. Finally, Jupiter Topco LLC purchased a new stake in shares of Carlsmed in the second quarter valued at $12,992,000.

Carlsmed Company Profile

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients. Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed’s technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.